Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial
Background: Cancer patients show increased morbidity with COVID-19 and need effective immunization strategies. Many healthcare regulatory agencies recommend administering ‘booster’ doses of COVID-19 vaccines beyond the standard two-dose series, for this group of patients. Therefore, studying the eff...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
eLife Sciences Publications Ltd
2023-03-01
|
Series: | eLife |
Subjects: | |
Online Access: | https://elifesciences.org/articles/83694 |
_version_ | 1797839258761822208 |
---|---|
author | Astha Thakkar Kith Pradhan Benjamin Duva Juan Manuel Carreno Srabani Sahu Victor Thiruthuvanathan Sean Campbell Sonia Gallego Tushar D Bhagat Johanna Rivera Gaurav Choudhary Raul Olea Maite Sabalza Lauren C Shapiro Matthew Lee Ryann Quinn Ioannis Mantzaris Edward Chu Britta Will Liise-anne Pirofski Florian Krammer Amit Verma Balazs Halmos |
author_facet | Astha Thakkar Kith Pradhan Benjamin Duva Juan Manuel Carreno Srabani Sahu Victor Thiruthuvanathan Sean Campbell Sonia Gallego Tushar D Bhagat Johanna Rivera Gaurav Choudhary Raul Olea Maite Sabalza Lauren C Shapiro Matthew Lee Ryann Quinn Ioannis Mantzaris Edward Chu Britta Will Liise-anne Pirofski Florian Krammer Amit Verma Balazs Halmos |
author_sort | Astha Thakkar |
collection | DOAJ |
description | Background: Cancer patients show increased morbidity with COVID-19 and need effective immunization strategies. Many healthcare regulatory agencies recommend administering ‘booster’ doses of COVID-19 vaccines beyond the standard two-dose series, for this group of patients. Therefore, studying the efficacy of these additional vaccine doses against SARS-CoV-2 and variants of concern is of utmost importance in this immunocompromised patient population
Methods: We conducted a prospective single arm clinical trial enrolling patients with cancer that had received two doses of mRNA or one dose of AD26.CoV2.S vaccine and administered a third dose of mRNA vaccine. We further enrolled patients that had no or low responses to three mRNA COVID vaccines and assessed the efficacy of a fourth dose of mRNA vaccine. Efficacy was assessed by changes in anti-spike antibody, T-cell activity, and neutralization activity, which were again assessed at baseline and 4 weeks.
Results: We demonstrate that a third dose of COVID-19 vaccine leads to seroconversion in 57% of patients that were seronegative after primary vaccination series. The immune response is durable as assessed by anti-SARS-CoV-2 (anti-S) antibody titers, T-cell activity, and neutralization activity against wild-type (WT) SARS-CoV2 and BA1.1.529 at 6 months of follow-up. A subset of severely immunocompromised hematologic malignancy patients that were unable to mount an adequate immune response (titer <1000 AU/mL) after the third dose and were treated with a fourth dose in a prospective clinical trial which led to adequate immune boost in 67% of patients. Low baseline IgM levels and CD19 counts were associated with inadequate seroconversion. Booster doses induced limited neutralization activity against the Omicron variant.
Conclusions: These results indicate that third dose of COVID vaccine induces durable immunity in cancer patients and an additional dose can further stimulate immunity in a subset of patients with inadequate response.
Funding: Leukemia Lymphoma Society, National Cancer Institute.
Clinical trial number: NCT05016622. |
first_indexed | 2024-04-09T15:55:06Z |
format | Article |
id | doaj.art-6208af8c6b20451080ddc36e3a95392b |
institution | Directory Open Access Journal |
issn | 2050-084X |
language | English |
last_indexed | 2024-04-09T15:55:06Z |
publishDate | 2023-03-01 |
publisher | eLife Sciences Publications Ltd |
record_format | Article |
series | eLife |
spelling | doaj.art-6208af8c6b20451080ddc36e3a95392b2023-04-25T17:22:59ZengeLife Sciences Publications LtdeLife2050-084X2023-03-011210.7554/eLife.83694Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trialAstha Thakkar0https://orcid.org/0000-0001-7778-0752Kith Pradhan1Benjamin Duva2Juan Manuel Carreno3Srabani Sahu4Victor Thiruthuvanathan5Sean Campbell6Sonia Gallego7Tushar D Bhagat8Johanna Rivera9Gaurav Choudhary10https://orcid.org/0000-0001-5365-6706Raul Olea11Maite Sabalza12Lauren C Shapiro13Matthew Lee14Ryann Quinn15Ioannis Mantzaris16Edward Chu17Britta Will18Liise-anne Pirofski19Florian Krammer20Amit Verma21https://orcid.org/0000-0002-5408-1673Balazs Halmos22https://orcid.org/0000-0001-7548-8360Department of Oncology, Montefiore Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, United StatesDepartment of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, United StatesDepartment of Oncology, Montefiore Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, United StatesDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, United States; Center for Vaccine Research and Pandemic Preparedness (C-VARPP), Icahn School of Medicine at Mount Sinai, New York, United StatesDepartment of Oncology, Montefiore Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, United StatesDepartment of Oncology, Montefiore Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, United StatesDepartment of Pathology, Montefiore Medical Center, Bronx, United StatesDepartment of Oncology, Montefiore Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, United StatesDepartment of Oncology, Montefiore Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, United StatesDepartment of Medicine, Albert Einstein College of Medicine, Bronx, United StatesDepartment of Oncology, Montefiore Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, United StatesDepartment of Oncology, Montefiore Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, United StatesEuroimmun, Mountain Lakes, United StatesDepartment of Oncology, Montefiore Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, United StatesDepartment of Oncology, Montefiore Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, United StatesDepartment of Oncology, Montefiore Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, United StatesDepartment of Oncology, Montefiore Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, United StatesDepartment of Oncology, Montefiore Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, United StatesDepartment of Oncology, Montefiore Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, United StatesDepartment of Medicine, Albert Einstein College of Medicine, Bronx, United StatesDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, United States; Center for Vaccine Research and Pandemic Preparedness (C-VARPP), Icahn School of Medicine at Mount Sinai, New York, United States; Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, United StatesDepartment of Oncology, Montefiore Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, United StatesDepartment of Oncology, Montefiore Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, United StatesBackground: Cancer patients show increased morbidity with COVID-19 and need effective immunization strategies. Many healthcare regulatory agencies recommend administering ‘booster’ doses of COVID-19 vaccines beyond the standard two-dose series, for this group of patients. Therefore, studying the efficacy of these additional vaccine doses against SARS-CoV-2 and variants of concern is of utmost importance in this immunocompromised patient population Methods: We conducted a prospective single arm clinical trial enrolling patients with cancer that had received two doses of mRNA or one dose of AD26.CoV2.S vaccine and administered a third dose of mRNA vaccine. We further enrolled patients that had no or low responses to three mRNA COVID vaccines and assessed the efficacy of a fourth dose of mRNA vaccine. Efficacy was assessed by changes in anti-spike antibody, T-cell activity, and neutralization activity, which were again assessed at baseline and 4 weeks. Results: We demonstrate that a third dose of COVID-19 vaccine leads to seroconversion in 57% of patients that were seronegative after primary vaccination series. The immune response is durable as assessed by anti-SARS-CoV-2 (anti-S) antibody titers, T-cell activity, and neutralization activity against wild-type (WT) SARS-CoV2 and BA1.1.529 at 6 months of follow-up. A subset of severely immunocompromised hematologic malignancy patients that were unable to mount an adequate immune response (titer <1000 AU/mL) after the third dose and were treated with a fourth dose in a prospective clinical trial which led to adequate immune boost in 67% of patients. Low baseline IgM levels and CD19 counts were associated with inadequate seroconversion. Booster doses induced limited neutralization activity against the Omicron variant. Conclusions: These results indicate that third dose of COVID vaccine induces durable immunity in cancer patients and an additional dose can further stimulate immunity in a subset of patients with inadequate response. Funding: Leukemia Lymphoma Society, National Cancer Institute. Clinical trial number: NCT05016622.https://elifesciences.org/articles/83694SARS CoV-2COVID-19vaccineimmunocompromisedcancer |
spellingShingle | Astha Thakkar Kith Pradhan Benjamin Duva Juan Manuel Carreno Srabani Sahu Victor Thiruthuvanathan Sean Campbell Sonia Gallego Tushar D Bhagat Johanna Rivera Gaurav Choudhary Raul Olea Maite Sabalza Lauren C Shapiro Matthew Lee Ryann Quinn Ioannis Mantzaris Edward Chu Britta Will Liise-anne Pirofski Florian Krammer Amit Verma Balazs Halmos Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial eLife SARS CoV-2 COVID-19 vaccine immunocompromised cancer |
title | Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial |
title_full | Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial |
title_fullStr | Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial |
title_full_unstemmed | Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial |
title_short | Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial |
title_sort | study of efficacy and longevity of immune response to third and fourth doses of covid 19 vaccines in patients with cancer a single arm clinical trial |
topic | SARS CoV-2 COVID-19 vaccine immunocompromised cancer |
url | https://elifesciences.org/articles/83694 |
work_keys_str_mv | AT asthathakkar studyofefficacyandlongevityofimmuneresponsetothirdandfourthdosesofcovid19vaccinesinpatientswithcancerasinglearmclinicaltrial AT kithpradhan studyofefficacyandlongevityofimmuneresponsetothirdandfourthdosesofcovid19vaccinesinpatientswithcancerasinglearmclinicaltrial AT benjaminduva studyofefficacyandlongevityofimmuneresponsetothirdandfourthdosesofcovid19vaccinesinpatientswithcancerasinglearmclinicaltrial AT juanmanuelcarreno studyofefficacyandlongevityofimmuneresponsetothirdandfourthdosesofcovid19vaccinesinpatientswithcancerasinglearmclinicaltrial AT srabanisahu studyofefficacyandlongevityofimmuneresponsetothirdandfourthdosesofcovid19vaccinesinpatientswithcancerasinglearmclinicaltrial AT victorthiruthuvanathan studyofefficacyandlongevityofimmuneresponsetothirdandfourthdosesofcovid19vaccinesinpatientswithcancerasinglearmclinicaltrial AT seancampbell studyofefficacyandlongevityofimmuneresponsetothirdandfourthdosesofcovid19vaccinesinpatientswithcancerasinglearmclinicaltrial AT soniagallego studyofefficacyandlongevityofimmuneresponsetothirdandfourthdosesofcovid19vaccinesinpatientswithcancerasinglearmclinicaltrial AT tushardbhagat studyofefficacyandlongevityofimmuneresponsetothirdandfourthdosesofcovid19vaccinesinpatientswithcancerasinglearmclinicaltrial AT johannarivera studyofefficacyandlongevityofimmuneresponsetothirdandfourthdosesofcovid19vaccinesinpatientswithcancerasinglearmclinicaltrial AT gauravchoudhary studyofefficacyandlongevityofimmuneresponsetothirdandfourthdosesofcovid19vaccinesinpatientswithcancerasinglearmclinicaltrial AT raulolea studyofefficacyandlongevityofimmuneresponsetothirdandfourthdosesofcovid19vaccinesinpatientswithcancerasinglearmclinicaltrial AT maitesabalza studyofefficacyandlongevityofimmuneresponsetothirdandfourthdosesofcovid19vaccinesinpatientswithcancerasinglearmclinicaltrial AT laurencshapiro studyofefficacyandlongevityofimmuneresponsetothirdandfourthdosesofcovid19vaccinesinpatientswithcancerasinglearmclinicaltrial AT matthewlee studyofefficacyandlongevityofimmuneresponsetothirdandfourthdosesofcovid19vaccinesinpatientswithcancerasinglearmclinicaltrial AT ryannquinn studyofefficacyandlongevityofimmuneresponsetothirdandfourthdosesofcovid19vaccinesinpatientswithcancerasinglearmclinicaltrial AT ioannismantzaris studyofefficacyandlongevityofimmuneresponsetothirdandfourthdosesofcovid19vaccinesinpatientswithcancerasinglearmclinicaltrial AT edwardchu studyofefficacyandlongevityofimmuneresponsetothirdandfourthdosesofcovid19vaccinesinpatientswithcancerasinglearmclinicaltrial AT brittawill studyofefficacyandlongevityofimmuneresponsetothirdandfourthdosesofcovid19vaccinesinpatientswithcancerasinglearmclinicaltrial AT liiseannepirofski studyofefficacyandlongevityofimmuneresponsetothirdandfourthdosesofcovid19vaccinesinpatientswithcancerasinglearmclinicaltrial AT floriankrammer studyofefficacyandlongevityofimmuneresponsetothirdandfourthdosesofcovid19vaccinesinpatientswithcancerasinglearmclinicaltrial AT amitverma studyofefficacyandlongevityofimmuneresponsetothirdandfourthdosesofcovid19vaccinesinpatientswithcancerasinglearmclinicaltrial AT balazshalmos studyofefficacyandlongevityofimmuneresponsetothirdandfourthdosesofcovid19vaccinesinpatientswithcancerasinglearmclinicaltrial |